Back to News

More Than 75 Emerging Biotechs Use ³Ô¹Ï±¬ÁÏ Basics Across Clinical, Regulatory, and Quality

Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies

PLEASANTON, CA - May 20, 2025 - ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced that is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of ³Ô¹Ï±¬ÁÏ Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow.

Designed specifically for fast-growing companies, ³Ô¹Ï±¬ÁÏ Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, ³Ô¹Ï±¬ÁÏ is adding two new applications for biotechs:

  • ³Ô¹Ï±¬ÁÏ CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications.
  • ³Ô¹Ï±¬ÁÏ Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system.

¡°More biotechs are adopting ³Ô¹Ï±¬ÁÏ Basics in North America and Europe, driving savings in time, cost, and effort,¡± said Steve Harper, general manager of ³Ô¹Ï±¬ÁÏ Basics. ¡°Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we¡¯re adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features.¡±

³Ô¹Ï±¬ÁÏ CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, ³Ô¹Ï±¬ÁÏ Basics applications allow customers to scale their technology infrastructure as they grow. For more on ³Ô¹Ï±¬ÁÏ Basics, visit .

What biotechs are saying about ³Ô¹Ï±¬ÁÏ Basics:

¡°I believe ³Ô¹Ï±¬ÁÏ Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations,¡± said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. ¡°As our company continues to grow, I am confident that ³Ô¹Ï±¬ÁÏ¡¯s platform can scale with us and help ensure we remain up to date as regulatory requirements evolve.¡±

¡°As we expand our studies to a larger scale, ³Ô¹Ï±¬ÁÏ eTMF Basics gives us more control of our data and process to ensure inspection readiness,¡± said Joe Thornton, associate director, clinical operations at Scancell. "Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies.¡±

¡°The global support and training provided with ³Ô¹Ï±¬ÁÏ Basics helps us gain maximum value from ³Ô¹Ï±¬ÁÏ¡¯s industry solution,¡± said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. ¡°With a simple path to go live and validation, ³Ô¹Ï±¬ÁÏ Basics has delivered significant time and resource savings.¡±

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

³Ô¹Ï±¬ÁÏ Forward-looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at .

###

Contact:

Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com